Researchers have established not only that high levels of nectin-2 expression are associated with better prognosis in acute myeloid leukemia [19], but Stamm H. et al. also initiated preliminary studies on the potential use of immune checkpoints targeting PVRL-2 as a therapeutic option for patients [18]. The gene discussed is NECTIN2; the disease is acute myeloid leukemia.